Developing an inactivated rotavirus vaccine and evaluating the immunogenicity against a commercially available attenuated rotavirus vaccine using a mice animal model
Hashim, A.S.M.; Aboshanab K.M.A; El-Sayed, A.F.M.;
Abstract
© Mary Ann Liebert, Inc. 2016. There is a high demand for public immunization against Rotavirus (RV), especially in Africa. In Africa, the attenuated RV vaccination is contraindicated in patients with immune diseases and nutrition deficiency. Therefore, the inactivated RV vaccine (IRVV) could be an alternative. In this study, we aimed to develop a pentavalent-IRVV using the most circulating RV strains in Egypt and evaluate it against the commercially available Rotarix® vaccine. Trial-IRVV was developed with 5% sucrose, 2% polysorbate-80, and adsorbed on Alum to potentiate the vaccine immune response. Then, it was injected subcutaneously into mice groups at 0-, 21-, and 35-time intervals. In parallel, Rotarix was administered twice on 0 and 28th day. The success of the pentavalent-IRVV/monovalent-Rotarix vaccine immunity rested on achieving immunoglobulin G (IgG) exceeding 1:6,400 that implies less susceptibility to RV infection (RVI). IRVV stimulating IgG >1:6,400 could be an alternative vaccination approach to reach a reasonable protective immunization level against RVI. In addition, Alum adjuvant incorporation effectively provoked a triple elevation of the immunization pattern.
Other data
Title | Developing an inactivated rotavirus vaccine and evaluating the immunogenicity against a commercially available attenuated rotavirus vaccine using a mice animal model | Authors | Hashim, A.S.M. ; Aboshanab K.M.A ; El-Sayed, A.F.M. | Issue Date | 2016 | Journal | Viral Immunology | DOI | 10 565 http://www.scopus.com/inward/record.url?eid=2-s2.0-85003533162&partnerID=MN8TOARS 29 1557-8976 10.1089/vim.2016.0073 |
PubMed ID | 29 | Scopus ID | 2-s2.0-85003533162 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.